,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,2015 Peel Street,11th Floor,Montreal,QC,H3A 1T8,Canada,514 336 7800,514 331 9691,https://www.theratech.com,Biotechnology,Healthcare,"Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.",144,"{'maxAge': 1, 'name': 'Mr. Paul  LÃ©vesque', 'age': 58, 'title': 'Pres, CEO & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 1309983, 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,8,5,1693526400,1672444800,86400,4,3.16,3.19,3.03,3.22,3.16,3.19,3.03,3.22,0.0,1.580829,-6.115385,27952,27952,76677,255160,255160,3.11,3.19,0,0,76961728,1.22,15.0,0.965776,2.7712,4.559,0.0,0.0,CAD,118264808,-0.45093,21671768,24201800,44616,3229,1690761600,1693440000,0.0018000001,0.59,0.0019,-1.716,1669766400,1701302400,1685491200,-35934000,-2.07,-0.52,-7.5,1.484,-7.91,TOR,EQUITY,TH.TO,TH.TO,THERATECHNOLOGIES,Theratechnologies Inc.,839338200,America/Toronto,EDT,-14400000,3.18,13.97,6.99,9.65,7.99,2.5,buy,3,25369000,1.048,-14952000,66672000,0.546,0.717,79689000,3.317,-0.13881,56219000,2945625,-14859000,-0.089,0.73894995,-0.18763,-0.22865999,USD,
1,2015 Peel Street,11th Floor,Montreal,QC,H3A 1T8,Canada,514 336 7800,514 331 9691,https://www.theratech.com,Biotechnology,Healthcare,"Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.",144,"{'maxAge': 1, 'name': 'Mr. Philippe  Dubuc M.B.A., MBA', 'age': 55, 'title': 'Sr. VP & CFO', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 449759, 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,8,5,1693526400,1672444800,86400,4,3.16,3.19,3.03,3.22,3.16,3.19,3.03,3.22,0.0,1.580829,-6.115385,27952,27952,76677,255160,255160,3.11,3.19,0,0,76961728,1.22,15.0,0.965776,2.7712,4.559,0.0,0.0,CAD,118264808,-0.45093,21671768,24201800,44616,3229,1690761600,1693440000,0.0018000001,0.59,0.0019,-1.716,1669766400,1701302400,1685491200,-35934000,-2.07,-0.52,-7.5,1.484,-7.91,TOR,EQUITY,TH.TO,TH.TO,THERATECHNOLOGIES,Theratechnologies Inc.,839338200,America/Toronto,EDT,-14400000,3.18,13.97,6.99,9.65,7.99,2.5,buy,3,25369000,1.048,-14952000,66672000,0.546,0.717,79689000,3.317,-0.13881,56219000,2945625,-14859000,-0.089,0.73894995,-0.18763,-0.22865999,USD,
2,2015 Peel Street,11th Floor,Montreal,QC,H3A 1T8,Canada,514 336 7800,514 331 9691,https://www.theratech.com,Biotechnology,Healthcare,"Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.",144,"{'maxAge': 1, 'name': 'Mr. Jocelyn  Lafond L.L.M., LL.B.', 'age': 54, 'title': 'Gen. Counsel & Corp. Sec.', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 325861, 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,8,5,1693526400,1672444800,86400,4,3.16,3.19,3.03,3.22,3.16,3.19,3.03,3.22,0.0,1.580829,-6.115385,27952,27952,76677,255160,255160,3.11,3.19,0,0,76961728,1.22,15.0,0.965776,2.7712,4.559,0.0,0.0,CAD,118264808,-0.45093,21671768,24201800,44616,3229,1690761600,1693440000,0.0018000001,0.59,0.0019,-1.716,1669766400,1701302400,1685491200,-35934000,-2.07,-0.52,-7.5,1.484,-7.91,TOR,EQUITY,TH.TO,TH.TO,THERATECHNOLOGIES,Theratechnologies Inc.,839338200,America/Toronto,EDT,-14400000,3.18,13.97,6.99,9.65,7.99,2.5,buy,3,25369000,1.048,-14952000,66672000,0.546,0.717,79689000,3.317,-0.13881,56219000,2945625,-14859000,-0.089,0.73894995,-0.18763,-0.22865999,USD,
3,2015 Peel Street,11th Floor,Montreal,QC,H3A 1T8,Canada,514 336 7800,514 331 9691,https://www.theratech.com,Biotechnology,Healthcare,"Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.",144,"{'maxAge': 1, 'name': 'Dr. Christian  Marsolais Ph.D.', 'age': 59, 'title': 'Sr. VP & Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 466810, 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,8,5,1693526400,1672444800,86400,4,3.16,3.19,3.03,3.22,3.16,3.19,3.03,3.22,0.0,1.580829,-6.115385,27952,27952,76677,255160,255160,3.11,3.19,0,0,76961728,1.22,15.0,0.965776,2.7712,4.559,0.0,0.0,CAD,118264808,-0.45093,21671768,24201800,44616,3229,1690761600,1693440000,0.0018000001,0.59,0.0019,-1.716,1669766400,1701302400,1685491200,-35934000,-2.07,-0.52,-7.5,1.484,-7.91,TOR,EQUITY,TH.TO,TH.TO,THERATECHNOLOGIES,Theratechnologies Inc.,839338200,America/Toronto,EDT,-14400000,3.18,13.97,6.99,9.65,7.99,2.5,buy,3,25369000,1.048,-14952000,66672000,0.546,0.717,79689000,3.317,-0.13881,56219000,2945625,-14859000,-0.089,0.73894995,-0.18763,-0.22865999,USD,
4,2015 Peel Street,11th Floor,Montreal,QC,H3A 1T8,Canada,514 336 7800,514 331 9691,https://www.theratech.com,Biotechnology,Healthcare,"Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.",144,"{'maxAge': 1, 'name': 'Mr. John  Leasure', 'age': 57, 'title': 'Global Commercial Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 513948, 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,8,5,1693526400,1672444800,86400,4,3.16,3.19,3.03,3.22,3.16,3.19,3.03,3.22,0.0,1.580829,-6.115385,27952,27952,76677,255160,255160,3.11,3.19,0,0,76961728,1.22,15.0,0.965776,2.7712,4.559,0.0,0.0,CAD,118264808,-0.45093,21671768,24201800,44616,3229,1690761600,1693440000,0.0018000001,0.59,0.0019,-1.716,1669766400,1701302400,1685491200,-35934000,-2.07,-0.52,-7.5,1.484,-7.91,TOR,EQUITY,TH.TO,TH.TO,THERATECHNOLOGIES,Theratechnologies Inc.,839338200,America/Toronto,EDT,-14400000,3.18,13.97,6.99,9.65,7.99,2.5,buy,3,25369000,1.048,-14952000,66672000,0.546,0.717,79689000,3.317,-0.13881,56219000,2945625,-14859000,-0.089,0.73894995,-0.18763,-0.22865999,USD,
5,2015 Peel Street,11th Floor,Montreal,QC,H3A 1T8,Canada,514 336 7800,514 331 9691,https://www.theratech.com,Biotechnology,Healthcare,"Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.",144,"{'maxAge': 1, 'name': 'Hon. Andre  Dupras M.Sc.', 'age': 58, 'title': 'VP of HR', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,8,5,1693526400,1672444800,86400,4,3.16,3.19,3.03,3.22,3.16,3.19,3.03,3.22,0.0,1.580829,-6.115385,27952,27952,76677,255160,255160,3.11,3.19,0,0,76961728,1.22,15.0,0.965776,2.7712,4.559,0.0,0.0,CAD,118264808,-0.45093,21671768,24201800,44616,3229,1690761600,1693440000,0.0018000001,0.59,0.0019,-1.716,1669766400,1701302400,1685491200,-35934000,-2.07,-0.52,-7.5,1.484,-7.91,TOR,EQUITY,TH.TO,TH.TO,THERATECHNOLOGIES,Theratechnologies Inc.,839338200,America/Toronto,EDT,-14400000,3.18,13.97,6.99,9.65,7.99,2.5,buy,3,25369000,1.048,-14952000,66672000,0.546,0.717,79689000,3.317,-0.13881,56219000,2945625,-14859000,-0.089,0.73894995,-0.18763,-0.22865999,USD,
